Eli Lilly on Thursday reported first-quarter earnings and income that blew previous estimates and hiked its full-year gross sales outlook by $2 billion, as demand for its blockbuster weight reduction drug Zepbound and diabetes remedy Mounjaro spiked once more.
The pharmaceutical large now expects 2026 income to come back in between $82 billion and $85 billion, up from a earlier steerage of $80 billion to $83 billion.
Lilly additionally expects its full-year adjusted revenue to be between $35.50 to $37 per share. That compares to a earlier outlook of $33.50 to $35 per share.
Resilient demand for Zepbound and Mounjaro has helped gasoline a number of robust quarters for Lilly regardless of decrease costs for the medicines within the U.S.
Mounjaro’s worldwide income rose 125% to $8.66 billion for the quarter, together with U.S. gross sales of $4.2 billion. That surpassed the $7.26 billion in worldwide gross sales that analysts have been anticipating for the quarter, in accordance with StreetAccount.
Zepbound, which entered the market roughly three years in the past, posted $4.16 billion in U.S. income for the primary quarter. That is up 80% from the year-earlier interval, as demand for the drug additionally rose whereas realized costs dropped. Analysts have been anticipating $4.04 billion in U.S. gross sales for Zepbound, in accordance with StreetAccount.
Lilly is working to take care of its dominance within the booming marketplace for GLP-1 medicine, with the corporate holding 60.1% share of the U.S. weight problems and diabetes drug market within the first quarter, in accordance with an earnings presentation. Novo’s market share within the quarter was 39.4%.
This is what Eli Lilly reported for the primary quarter in contrast with what Wall Road was anticipating, based mostly on a survey of analysts by LSEG:
- Earnings per share: $8.55 adjusted vs. $6.66 anticipated
- Income: $19.80 billion vs. $17.62 billion anticipated
Shares of Lilly rose greater than 7% in premarket buying and selling Thursday.
The corporate posted fourth-quarter income of $19.80 billion, up 56% from the identical interval a yr in the past.
“Impressively, it is like our fifth or sixth quarter in a row posting actually robust topline development numbers,” Lilly CEO Dave Ricks instructed CNBC in an unique interview on Thursday. “That is not normally one thing that pharmaceutical corporations of our dimension do.”
Income within the U.S. climbed 43% to $12.1 billion. Eli Lilly stated that was pushed by a 49% enhance in quantity — or the variety of prescriptions or models offered — for its merchandise, primarily for Mounjaro and Zepbound. That was partially offset by decrease realized costs of Zepbound and one other treatment for psoriatic arthritis and different situations, the corporate stated.
Notably, income exterior the U.S. jumped 81% to $7.7 billion, pushed by a 95% enhance in quantity and partly offset by decrease realized costs.
Ricks stated Lilly had slowed down introductions in world markets when it skilled provide constraints in late 2024. However he stated now Lilly is hitting its third or fourth quarter within the main markets throughout Europe, China and Brazil, the place many sufferers are paying out of pocket.
“As these launches hit stride, you are seeing the depth and breadth of the buyer market right here,” Ricks stated, referring to worldwide markets.
The pharmaceutical large booked web earnings of $7.40 billion, or $8.26 per share, for the primary quarter. That compares with web earnings of $2.76 billion, or $3.06 per share, a yr earlier.
Excluding one-time gadgets related to the worth of intangible property and different changes, Eli Lilly posted earnings of $8.55 per share for the primary quarter.
The corporate’s newly accepted GLP-1 capsule for weight problems, Foundayo, launched within the second quarter, so its gross sales should not included in Thursday’s report.
Nonetheless, the capsule’s rollout is prone to dominate the dialogue throughout Lilly’s first-quarter earnings name. Executives will possible face questions on whether or not Foundayo can attain the similar stage of momentum because the rival Wegovy capsule from Novo Nordisk, which benefited from a three-month head begin within the U.S.
In an unique interview with CNBC on Thursday, Eli Lilly CEO David Ricks stated greater than 20,000 individuals have began taking Foundayo in its first few weeks available on the market. Greater than 1,000 individuals a day are beginning the drug, he added.
He stated 80% of sufferers taking the drug are new to taking GLP-1s.
Ricks added that the corporate must construct client consciousness round Foundayo, noting that the corporate has not marketed it on TV.
“So what we’re seeing now could be mainly natural demand, which is de facto robust to us,” Ricks stated.
In February, Lilly stated it expects to profit from Foundayo’s launch, Medicare protection of weight problems medicine coming on-line later this yr and continued worldwide demand for Mounjaro and Zepbound. However the firm additionally expects to face pricing strain, pushed by a drug pricing take care of President Donald Trump and decrease cash-pay costs for Zepbound, amongst different elements.
Nonetheless, Ricks stated in an interview in late April that he expects decrease costs to speed up prescription volumes within the U.S. He additionally estimated that world GLP-1 use will rise from roughly 20 million sufferers on the finish of final yr to 30 million on the finish of 2026.
— CNBC’s Angelica Peebles contributed to this report